

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of: **Pratt**

Application No.: **Not Yet Assigned**

Filed: **March 23, 2004**

For: **Methods for Treating Parkinson's Disease**

Attorney Docket No: **109536.153 US3**

Commissioner of Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**


Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant brings to the Examiner's attention the documents listed on the attached PTO-1449 Form.

The submission of this Information Disclosure Statement does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art.

Pursuant to 37 C.F.R. § 1.98(d), the documents listed on the attached PTO-1449 form are not being submitted herewith since they were previously cited by the Applicant or the PTO in parent Application No. 10/321,653 or grandparent Application No. 09/899,028, to which the present application claims priority.

This Information Disclosure Statement is being filed with the application. Accordingly, no fee is due.

Respectfully submitted,

  
Edward D. Grieff  
Registration No. 38,898

Date: March 23, 2004  
HALE AND DORR LLP  
1455 Pennsylvania Avenue, NW  
Washington, DC 20004  
Phone: (202) 942-8400

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

109536.153 US2

**BEST AVAILABLE COPY**

**Considered**

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

+

Please type a plus sign (+) inside this box →



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	
			Filing Date	December 18, 2002
			First Named Inventor	Pratt
			Group Art Unit	
			Examiner Name	
			Attorney Docket Number	109536.153 US2
Sheet	2	of	3	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Ott et al, Clinical Neuropharmacology, 15(4):322-325 (1992).	
		Losev et al, Zh Nevropatol Psikhiatr Im S S Korsakova, 85(3):376-381 (1985) (English language translation of Russian article).	X
		Shea et al, International Psychogeriatrics, 10(3):229-238 (1998).	
		Kaufer et al, Neurology, 51:1512 (November 1998).	
		Aarsland et al, Neurology, 56(Suppl 3):A128 Abstract P02.105 (April 2001).	
		Lang et al, The New England Journal of Medicine, 339(16):1130-1143 (October 15, 1998).	
		Mendez et al, J. Neuropsychiatry Clin. Neurosci., 11:268-270 (May 1999).	
		Hasegawa et al, Folia Pharmacologica Japonica, 114(6):327-336 (December 1999).	
		CA 135:147270, Fabbrini et al, Acta Neurol. Scand., 2001, 103(2), 123-125, ABSTRACT.	
		DRUG U 1999-16501, Henneberg, J. Neural. Transm. 106(3-4), XXV-XXVI, 1999, ABSTRACT.	
		Hutchinson et al, Journal of Neurology, Neurosurgery, and Psychiatry, 61:324-325 (1996).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

BEST AVAILABLE COPY

Please type a plus sign (+) inside this box →



PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			<b>Application Number</b>		
			<b>Filing Date</b> December 18, 2002		
			<b>First Named Inventor</b> Pratt		
			<b>Group Art Unit</b>		
			<b>Examiner Name</b>		
<b>Sheet</b>	3	<b>of</b>	3	<b>Attorney Docket Number</b> 109536.153 US2	

<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>			
<b>Examiner Initials*</b>	<b>Cite No.<sup>1</sup></b>	<b>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>	<b>T<sup>2</sup></b>
		Henneberg, J. Neural. Transm., 106(3-4), pages XXV-XXVI (April 21, 1999), Full Journal Article.	
		Fabbrini et al, Acta. Neurol. Scand., 103(2):123-125 (2001), Full Journal Article.	
		Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., American Psychiatric Association, pages 164-167 (2000).	
		Lepine-Haudot et al, Pharmacy World & Science, 22(1), page A27, Abstract No. 45 (2000).	

BEST AVAILABLE COPY

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.